Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy.

  • NORLUX Neuro-Oncology Laboratory
August 01, 2017 By:
  • Neirinckx V
  • Hedman H
  • Niclou SP.

Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.

2017 Aug. Biochim Biophys Acta-Rev Cancer.1868(1):109-116. Epub 2017 Mar 1.
Other information